However, data indicate that certain populations of men at intermediate or high risk may derive benefit from treatment of PCa.[33] Because PSA and DRE are not highly sensitive tests, there is no threshold below which men will not be diagnosed with PCa, and there is currently no test that can accurately predict whether men with low risk disease (i.e.- Gleason 3+3 = 6, cT1c or cT2a, and PSA <10ng/ml) will continue on an indolent course or progress to more aggressive disease. The gene discussed is KLK3; the disease is posterior cortical atrophy.